Safety first

Peptides, the grey market, and staying safe

Today, Americans are playing Peptide Roulette with every unregulated shot they inject. We're pushing the federal government for a Peptide Verified environment, because you should know what's actually in your shot.

Peppies does not sell peptides and does not tell anyone to use them. But people are buying them anyway - mostly from an unregulated grey market - so the most useful thing an independent resource can do is help you understand the risks, report a problem to the FDA, and tell a legitimate, licensed pharmacy from an anonymous seller. This page is plain-English and cited.

None of the seven peptides under FDA review is FDA-approved, and Peppies does not sell any of them. Products sold online as "research use only - not for human consumption" are outside the regulated system. If you have had a bad reaction to any product, the single most important step is to report it to the FDA - below.

If something goes wrong, report it to the FDA

Reporting is free, takes a few minutes, and is how the FDA detects patterns of harm. It is also, quietly, one of the most useful things a consumer can do - the agency's own adverse-event data is part of what its scientists rely on. You do not need to be certain a product caused the problem to report it.

Report a bad reaction (MedWatch)

For a serious side effect, injury, or suspected reaction - anything from an infection at an injection site to shortness of breath. Consumers can file directly.

Report to MedWatch →

Or call 1-800-332-1088

Report a bad product or an illegal seller

For a product that looks contaminated, mislabeled, or counterfeit, or a website illegally selling drugs to consumers - use the FDA's general problem-reporting portal.

Report a problem to the FDA →

Consumer form: FDA Form 3500B (PDF)

Why the grey-market product is risky

The core problem isn't a moral one - it's that no one is checking what's in the vial. When a product moves outside the regulated system, there is no verification of identity, potency, or sterility, and independent testing keeps finding that the contents don't match the label.

Purity

Testing of falsified peptide products found purity ranging from 5% to 75%, with arsenic and lead above the limits set for injectable drugs.

Janvier et al., Talanta, 2018

Contamination

A 2026 ECRI & ISMP patient-safety white paper warned that grey-market peptides - naming BPC-157, TB-500 and others - carry contamination and dosing risks.

ECRI & ISMP, 2026

Enforcement gap

Of 14 retatrutide vendors that had received FDA warning letters, 8 were still actively selling months later - enforcement "stalled at the warning-letter stage."

CBS News investigation, via Medscape, 2026

See all the cited figures →

This isn't hypothetical - the grey market is hurting people

"Peptide roulette" isn't a slogan; it's a record. Below is a sample of what is documented when there is no legal, tested pathway and no one verifies what's in the vial. Each links to its source.

What's in the vial?

A reporter bought a vial labeled "retatrutide" over the counter; its lab certificate was forged - the sample actually tested as a different drug, tirzepatide.

CBS News investigation, 2026

Documented harm

Australia moved the tanning peptide Melanotan II to its prohibited schedule in 2026 after 89 adverse-event reports, including melanoma. (Not one of the seven under review.)

Australia's TGA, 2026

Dosing errors

The FDA warned that dosing errors with compounded injections led people to inject 5-20× the intended dose; deaths and hospitalizations followed in its adverse-event data. (A GLP-1 drug, not one of the seven.)

FDA safety alert, 2024

Poison control

U.S. poison-center exposures tied to one grey-market weight-loss peptide (retatrutide) rose 265% in early 2026. (Not one of the seven.)

CBS News, via Medscape, 2026

Regulators acting

Health Canada seized unauthorized injectable peptides in 2025-26, warning they can cause infections, blood clots, and organ damage, and is blocking shipments at the border.

Health Canada, 2025-26

The seven, specifically

In its own briefing on the seven, the FDA logged adverse-event reports for BPC-157 - including a consumer who went to the ER with shortness of breath, and skin and gum darkening after a "research use only" blend.

FDA PCAC briefing, 2026

Two honest points. First, these show harm can happen, not how often - most are individual case reports or voluntary filings, which can't establish how common a problem is. Second, the most severe documented cases involve peptides that are not among the seven under review (Melanotan II, retatrutide, compounded GLP-1s). The seven's problem is different but no less real: no one has the human safety data at all, because the products are unapproved and untested. The through-line is the same every time - an unregulated market where no one verifies what's in the vial. That is peptide roulette, and a legal, tested pathway is how it ends.

Licensed compounding is not the grey market

This distinction gets lost in most coverage, and it matters. A licensed compounding pharmacy is a regulated business: it operates under a state board of pharmacy, follows U.S. Pharmacopeia (USP) standards for how sterile medications are made, dispenses against a prescription, and can be inspected. An anonymous online seller shipping "research" powder is none of those things. When people conflate the two, they tar the legitimate, accountable channel with the sins of the black market.

Licensed compounding pharmacy

Licensed and inspected by a state board of pharmacy
Follows USP standards for sterile compounding (<795>/<797>/<800>)
Requires a valid prescription from a licensed prescriber
A named, licensed pharmacist is accountable for the product
Can be traced, audited, and held responsible if something goes wrong

Unregulated grey-market seller

No license, no inspection, often shipped from overseas
No verified identity, potency, or sterility testing
No prescription; hides behind "research use only" labels
Anonymous - often an encrypted app or a disposable storefront
No accountability if the product is contaminated or mislabeled

What is compounding, in plain English?

Compounding is the long-established practice of a licensed pharmacy preparing a customized medication for a patient. It is regulated under two parts of federal law:

503A: Traditional pharmacies compounding for an individual patient with a prescription. For a substance that isn't part of an FDA-approved drug, it generally has to be on the FDA's 503A Bulk Drug Substances List to be eligible - which is exactly what the July 2026 advisory meeting is about.
503B: "Outsourcing facilities" that make larger batches under stricter, FDA-registered manufacturing standards, and are inspected on a risk-based schedule.
The oversight stack: State boards of pharmacy license and inspect pharmacies; the U.S. Pharmacopeia (USP) sets the sterile-compounding standards; and 503B facilities register with and are inspected by the FDA.

Official reference: FDA - bulk drug substances under 503A.

How to tell a licensed pharmacy from an illegal seller

If you are looking at a website, these are the practical tells. A legitimate pharmacy will have most or all of them; an illegal seller will be missing several.

A prescription is required. Legitimate compounding is dispensed against a prescription from a licensed prescriber. "No prescription needed" is a red flag.
A verifiable state pharmacy license. Real pharmacies list their license and can be checked with the state board of pharmacy.
A named pharmacist and a physical address - not an anonymous storefront or a messaging-app handle.
No "research use only / not for human consumption" dodge. That label is how sellers try to route around the law; it is a warning sign, not a reassurance.
Straight answers on testing. A legitimate operation can speak to identity, potency, and sterility testing. "Trust us" is not testing.

Not everything belongs in a compounding pharmacy

Being pro-safety cuts both ways. Even the compounding industry's own advocates agree that some substances shouldn't be compounded - the Alliance for Pharmacy Compounding has been explicit, for example, that there is no legal basis to compound a patented, investigational drug like retatrutide. A serious safety position isn't "everything, for everyone"; it's a legal, tested channel for the substances that genuinely qualify, and a firm line against the ones that don't. That is the line Peppies takes too.

See also: who's who in the debate · the retatrutide explainer on the numbers page.

Where to check official information

The FDA docket

FDA-2025-N-6895 - comments & materials

The advisory meeting

July 23-24, 2026 PCAC notice

FDA on the safety risks

The agency's own risk statement

FDA drug shortage list

What is and isn't in shortage

Peppies does not sell, promote, or facilitate the sale of any peptide, and will not unless and until it is legal to do so. This page is educational information, not medical advice, and is not a substitute for talking to a licensed clinician. Statements about peptides have not been evaluated by the FDA.